Overview
Our laboratory is interested in understanding the molecular and genetic events underlying cancer progression and metastasis. The focus of our work is a series of genetically engineered mouse models that faithfully recapitulate human disease. Using a combination of mouse genetics, omics technologies, cross-species analyses and in vitro approaches, we aim to identify cancer cell–intrinsic and –extrinsic mechanisms driving metastatic cancer progression, with a long–term goal of developing new therapeutic strategies for preventing and treating metastatic disease.
Current Appointments & Affiliations
Associate Professor of Pathology
·
2022 - Present
Pathology,
Clinical Science Departments
Associate Research Professor of Cell Biology
·
2022 - Present
Cell Biology,
Basic Science Departments
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Comparative analysis of gene regulation in single cells using Compass.
Journal Article Cell Rep Methods · April 30, 2025 Single-cell multi-omics is a transformative technology that measures both gene expression and chromatin accessibility in individual cells. However, most studies concentrate on a single tissue and are unable to determine whether a gene is regulated by a cis ... Full text Open Access Link to item CiteVaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer.
Journal Article Vaccines (Basel) · November 13, 2024 Background/Objectives: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to target thi ... Full text Link to item CiteIMPA1-derived inositol maintains stemness in castration-resistant prostate cancer via IMPDH2 activation.
Journal Article J Exp Med · November 4, 2024 Acquisition of prostate cancer stem cells (PCSCs) manifested during androgen ablation therapy (ABT) contributes to castration-resistant prostate cancer (CRPC). However, little is known about the specific metabolites critically orchestrating this process. H ... Full text Link to item CiteRecent Grants
Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2022 - 2027Targeting Ferroptosis in Lethal RB1 Deficient Prostate Cancer
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2022 - 2027Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology for Prostate Cancer
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2022 - 2027View All Grants
Education, Training & Certifications
University of Rochester ·
2009
Ph.D.